Significant Research Findings: Castle Biosciences' latest study demonstrates that combining DecisionDx-UM with PRAME gene expression data significantly enhances predictive accuracy for metastatic risk in uveal melanoma patients compared to standalone gene mutation analysis, thereby providing a more reliable basis for clinical decision-making.
Large Sample Size: The study analyzed 1,140 primary uveal melanoma tumor samples, including 131 early-stage small tumors, validating the new method's applicability across different tumor stages and showcasing its potential in early detection.
Broad Clinical Application: By offering more comprehensive risk stratification, the DecisionDx-UM and PRAME combination not only improves patient survival outcomes but also aids physicians in developing personalized treatment plans, enhancing overall patient care effectiveness.
Elevating Industry Standards: Since 2009, DecisionDx-UM has been part of the standard of care in the U.S., and with the new research findings, Castle Biosciences further solidifies its leadership position in the uveal melanoma diagnostics field, likely driving more patients to adopt this innovative testing approach.
CSTL
$39.05+Infinity%1D
Analyst Views on CSTL
Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.880
Low
23.56
Averages
34.39
High
41.00
Current: 38.880
Low
23.56
Averages
34.39
High
41.00
BTIG
Mark Massaro
Buy
upgrade
$38 -> $50
2025-12-12
New
Reason
BTIG
Mark Massaro
Price Target
$38 -> $50
2025-12-12
New
upgrade
Buy
Reason
BTIG analyst Mark Massaro raised the firm's price target on Castle Biosciences to $50 from $38 and keeps a Buy rating on the shares as part of a broader research note reviewing 2025 for Diagnostics and Tools. The firm is also positive on the stock's risk-reward, adding that at 2.6-times sales, the stock has a best-in-class financial profile, the analyst tells investors in a research note.
Baird
NULL -> Outperform
maintain
$39 -> $41
2025-11-04
Reason
Baird
Price Target
$39 -> $41
2025-11-04
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Castle Biosciences to $41 from $39 and keeps an Outperform rating on the shares. The firm updated its model following solid Q3 results and raised revenue outlook.
Scotiabank
Outperform
downgrade
$44 -> $40
2025-05-21
Reason
Scotiabank
Price Target
$44 -> $40
2025-05-21
downgrade
Outperform
Reason
Scotiabank lowered the firm's price target on Castle Biosciences to $40 from $44 and keeps an Outperform rating on the shares. The company raised its full year guidance despite DecisionDx-SCC no longer being reimbursed by Medicare and the discontinuation of IDgenetix, the analyst tells investors. The company remains on track to launch a therapy guidance test for atopic dermatitis by the end of 2025, the firm adds.
Baird
Catherine Ramsey
Buy
Maintains
$36 → $37
2025-02-28
Reason
Baird
Catherine Ramsey
Price Target
$36 → $37
2025-02-28
Maintains
Buy
Reason
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
